IRMD

Analyst Note: IRMD (IRadimed Corporation)

Date: 2026-06-13 Event Date: 2026-06-13

1. Structural Readiness

• Current Price: $92.20
• Breakout Level (Resistance): $107.90
• Conservative Entry: None (Breakout not yet fired)
• Aggressive Entry: $96.00 (Pre-breakout / forming entry)
• Extension: —
• ATR Context: Current ATR is 4.0% (High bucket). ATR at breakout is not yet recorded.

Analysis:

2. Thesis Layer

As of 2026-06-13, there is NO named secular thesis attached to this setup. This is a TACTICAL, setup-led name.

The investment case must be judged strictly on the quality of the technical structure (the forming coil) and the immediate business fundamentals provided in the recent earnings data. Do not invent a macro narrative. The conviction stack relies entirely on the alignment of the forming price structure with the company's execution of its product launch and guidance.

3. Business Overview

Company: IRadimed Corporation (IRMD) Industry: Healthcare / Medical Devices Business Model: Engineering, production, and distribution of MRI-compatible medical devices, specifically non-magnetic IV infusion pumps and patient monitoring systems. The company sells primarily to hospitals and acute care facilities in the U.S. and internationally.

Key Business Drivers (as of May 2026):

• Product Launch Execution: The company is in the early commercialization phase of its new MRidium 3870 IV infusion pump system. FDA 510(k) clearance was received in May 2025, with the first customer shipment completed in December 2025.
• Revenue Growth: For the three months ended March 31, 2026, total revenue increased 13% year-over-year to $22.0 million (from $19.5 million). Device sales specifically grew 19% to $15.4 million.
• Guidance & Outlook:
• Q2 2026 Guidance: Revenue expected between $20M and $21M; GAAP EPS $0.40–$0.44; Non-GAAP EPS $0.44–$0.48.
• FY 2026 Guidance: Revenue expected between $91M and $96M; GAAP EPS $1.90–$2.05; Non-GAAP EPS $2.06–$2.21.
• Product Mix & Pricing: Management reports that initial quoting and orders for the 3870 show a lift closer to 20% of the 3860 ASP (Average Selling Price). The majority of new business is for Quad (4-pump) systems rather than simple dual-channel replacements.
• Market Opportunity: Management estimates a replacement opportunity of approximately 6,400 channels in the U.S. for units older than 5 years. They target adding 1,000 channels per year to replacement sales from this base. Globally, they estimate a potential market of 27,350 MRI-compatible IV infusion pump systems.
• Operational Efficiency: Gross profit margin increased to 77% in Q1 2026 (vs. 76% in Q1 2025). The company maintains a direct U.S. sales force of 29 field representatives, 4 regional directors, and 10 clinical specialists.

4. Archetype and Conviction

Archetype: Quality Compounder This classification fits the company's profile of high-margin, niche-market dominance with a clear path to revenue expansion via a new product generation.

• Margin Inflector: The company demonstrates strong pricing power and operational leverage, evidenced by the 77% gross margin and the 20% ASP lift on the new 3870 system compared to the legacy 3860.
• Structural Quality: The business is a "Quality Compounder" because it holds a unique market position (only known provider of non-magnetic IV pumps for MRI) and is executing a planned product lifecycle transition (discontinuing 3860+ in 2026) without apparent disruption.
• Valuation Context: The financial spine indicates a forward consensus EPS of $2.075 for FY1 and $2.355 for FY2. This aligns with management's non-GAAP guidance of $2.06–$2.21 for FY2026, suggesting the market consensus is pricing in the management's optimistic outlook.
• Conviction Stack:
• *Thesis Strength:* Low (Tactical only).
• *Evidence Quality:* High (Recent earnings, clear guidance, specific order metrics).
• *Setup Readiness:* Partial (Forming, awaiting breakout).
• *Rerating Potential:* Moderate (Dependent on breakout confirmation and sustained order flow).

5. Invalidations, Strengtheners, and Gaps

What Would Invalidate:

• Fundamental: A significant miss on Q2 2026 guidance (Revenue < $20M or EPS < $0.40) or a clear signal that the 3870 order flow is slowing below the targeted 1,000 channels/year.

What Would Strengthen:

• Technical: A daily close above $107.90 (Breakout level). This would convert the setup to "Confirmed-Active."
• Fundamental: Confirmation that the 3870 launch is driving the majority of the Q2 revenue beat, or an update showing the "Quad system" mix is expanding faster than expected.

Gaps in Evidence:

• Order Backlog: While management mentions "orders well ahead of expectations," specific backlog dollar amounts or conversion rates from quote to order are not detailed in the provided evidence.
• International Mix: The evidence highlights U.S. replacement cycles but provides less granular data on the international sales contribution relative to the global 27,350 unit estimate.
• Competitive Landscape: No specific data on potential new entrants or competitive threats beyond the "only known provider" claim.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key risks: Technical setup remains unconfirmed (price below $107.90 breakout); High ATR (4.0%) indicates elevated volatility risk; Product launch execution risk if 3870 order flow fails to meet 1,000 channel/year target. Sizing hint: Position size should reflect the partial readiness of the forming coil; smaller than a confirmed breakout setup. Expected path: Price consolidates near current levels while management executes Q2 shipping targets; a breakout above $107.90 would confirm the setup and likely lead to a re-rating based on the FY2026 guidance. Expected horizon: 3 to 6 months for the breakout or invalidation to resolve. Failure mode to watch: A daily close below $87.91, which would invalidate the forming coil structure and suggest a loss of technical support.